98%
921
2 minutes
20
Extracranial arteriovenous malformation (AVM) is a congenital vascular anomaly causing disfigurement, bleeding, ulceration, and pain. Most lesions are associated with somatic MAP2K1 activating mutations in endothelial cells (ECs). The purpose of this study was to determine if EC expression of mutant activated MAP2K1 is sufficient to produce vascular malformations in mice. We generated mice with a ROSA26 allele containing a lox-stop-lox gene trap (GT), Map2k1 cDNA with an activating p.K57N missense mutation, an internal ribosomal entry site, and green fluorescent protein cDNA (R26). We expressed mutant MAP2K1 and GFP in ECs of fetal and newborn mice using Tg-Cdh5Cre or Tg-Cdh5CreER alleles. Tg-Cdh5Cre;R26 animals that express mutant MAP2K1 in ECs in utero developed diffuse vascular abnormalities and died by embryonic (E) day 16.5. Tg-Cdh5CreER;R26 animals in which mutant MAP2K1 expression was induced in ECs by tamoxifen at postnatal (P) day 1 developed vascular malformations in the brain, ear, and intestines by P23. The lesions consisted of abnormal networks of blood vessels containing recombined and non-recombined ECs. In conclusion, expression of MAP2K1 p.K57N is sufficient to cause vascular malformations in mice. This model can be used to study the malformation process and for pre-clinical pharmacologic studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918623 | PMC |
http://dx.doi.org/10.1007/s10456-022-09853-6 | DOI Listing |
Nat Commun
September 2025
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
CRAF (RAF1) is one of three RAF-family kinases that initiate MAP kinase signaling in response to activated RAS and is essential for oncogenic signaling from mutant KRAS. Like BRAF, CRAF is regulated by 14-3-3 engagement and by intramolecular autoinhibitory interactions of its N-terminal regulatory region. Unlike BRAF, it is thought to require tyrosine phosphorylation in its N-terminal acidic (NtA) motif for full catalytic activation.
View Article and Find Full Text PDFVirchows Arch
July 2025
Department of Pathology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Extracranial arteriovenous malformations (AVMs) are rare aggressive vascular malformations, and half of AVMs harbor mutations in the RAS/RAF/MAPK pathway. AVMs consist of abnormal networks of small vessels formed between arteries and veins. Although the abnormal small-vessel networks are considered to cause AVM progression, the underlying mechanisms remain poorly understood.
View Article and Find Full Text PDFBMC Cancer
July 2025
Department of Molecular Pathology, Dokuz Eylul University Graduate School of Health Sciences, Izmir, 35330, Turkey.
Background: Micropapillary carcinoma (MPC) is a type of tumor that is histopathologically characterized by the presence of small papillary structures. Literature data on somatic mutations in MPCs are very limited.
Methods: One hundred fifty-nine colon resection cases diagnosed with adenocarcinoma whose DNA mutations were analyzed by next-generation sequencing (NGS) were retrospectively reviewed.
PLoS One
June 2025
The Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Cancers with TERT promoter mutations (TPM) display elevated RAS pathway signaling and mesenchymal traits, and associate with lower patient survival rates. We examined whether RAS pathway signaling in TPM cancers cooperates with mesenchymal features to drive resistance to apoptosis. We observed that RAS pathway signaling in TPM cancers inhibited apoptosis by downregulating the pro-apoptotic protein BIM.
View Article and Find Full Text PDFBiochem Pharmacol
September 2025
Guangzhou Key Laboratory of Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, PR China. Electronic address:
Pancreatic cancer is a highly aggressive malignancy with poor prognosis and high mortality rates. KRAS mutations are ubiquitous in pancreatic cancer, driving tumorigenesis by promoting uncontrolled cell proliferation, survival, and metastasis. Therefore, identifying therapeutic agents effective against KRAS-mutant pancreatic cancer is urgently needed.
View Article and Find Full Text PDF